Blinatumomab Linked to Higher Costs, Hospitalizations for R/R ALL - Cancer Therapy Advisor

Mean total cost of care was $65,437 for blinatumomab, $55,995 for inotuzumab, and $17,520 for other agents.

The costs per patient per month associated with novel CD-targeting therapies for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) were much higher compared with other agents… [+2808 chars]

full article...